Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.

Nature medicine - 1 Jan 2020

Drilon Alexander, Clark Jeffrey W, Weiss Jared, Ou Sai-Hong Ignatius, Camidge D Ross, Solomon Benjamin J, Otterson Gregory A, Villaruz Liza C, Riely Gregory J, Heist Rebecca S, Awad Mark M, Shapiro Geoffrey I, Satouchi Miyako, Hida Toyoaki, Hayashi Hidetoshi, Murphy Danielle A, Wang Sherry C, Li Sherry, Usari Tiziana, Wilner Keith D, Paik Paul K

Abstract excerpt

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a multikinase inhibitor with potent activity against MET3. The antitumor activity and safety of crizotinib were assessed in 69 patients with advanced NSCLCs harboring MET exon 14 alterations. Objective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crizotinib

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 31932802
DOI: 10.1038/s41591-019-0716-8
PMCID: PMC8500676

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.PMID 31932802Read ↗

Multikinase Inhibitor Crizotinib Is Active in MET Exon 14-Altered Lung Cancer.Semantic proximity Read ↗

Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.Semantic proximity Read ↗

Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.Semantic proximity Read ↗

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancersSemantic proximity Read ↗

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

Targeting un-MET needs in advanced non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.Semantic proximity Read ↗

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.Semantic proximity Read ↗

A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.Semantic proximity Read ↗

Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.Semantic proximity Read ↗

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.